Lexicon Pharmaceuticals, Inc. Stock News

THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was pu...

THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C.

Lexicon Pharmaceuticals currently offers three late-stage assets - Zynquista, Inpefa, and pilavapadin - each with high-reward potential but significant regulatory and commercial risks. Zynquista's renewed FDA engagement for Type 1 diabetes could enable resubmission in early 2026, but commercial execution and reimbursement remain key hurdles. Inpefa's HCM Phase III readout is expected in Q1'27, ...

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET.

Lexicon Pharmaceuticals, Inc. ( LXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division Thank you, everyone, for tuning in. I'm Andrew Tsai...

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval in Type 1 diabetes and hypertrophic cardiomyopathy, but new data and ongoing trials offer near-term catalysts. Novo Nordisk partnership on LX9851 and improved pilavapadin data provide financial sup...

THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m.

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sotagliflozin treatment in heart failure patients with preserved ejection fraction (HFpEF), and without diabetes, across a range of measures,...